Literature DB >> 19521965

EUROGIN 2008 roadmap on cervical cancer prevention.

Silvia Franceschi1, Jack Cuzick, Rolando Herrero, Joakim Dillner, Cosette M Wheeler.   

Abstract

The EUROGIN 2008 Roadmap represents a continuing effort to provide updated information on primary and secondary prevention of cervical cancer. The report addresses several areas including the progress made toward global implementation of currently licensed human papillomavirus (HPV) vaccines, the possibilities and value of future-generation HPV vaccines, endpoints under consideration for evaluation of candidate HPV vaccines, and monitoring impact of HPV vaccination programmes that can be implemented within developed and less-developed countries. For the sake of completeness, a short update on the evolution of HPV testing in primary screening programmes at present and after HPV vaccine introduction has also been included. The report is available on the EUROGIN website (www.eurogin.com).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19521965     DOI: 10.1002/ijc.24634

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

Review 1.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

2.  Trends in the cervical cancer screening rates in a city in Japan between the years of 2004 and 2013.

Authors:  Yusuke Tanaka; Yutaka Ueda; Hisayo Kishida; Noriko Hosogai; Akiko Morimoto; Tomomi Egawa-Takata; Shinya Matsuzaki; Eiji Kobayashi; Kiyoshi Yoshino; Tadashi Kimura
Journal:  Int J Clin Oncol       Date:  2015-05-20       Impact factor: 3.402

3.  Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.

Authors:  Jessica A Kahn; Robert D Burk; Kathleen E Squires; Bill G Kapogiannis; Bret Rudy; Jiahong Xu; René Gonin; Nancy Liu; Carol Worrell; Craig M Wilson
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

4.  Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA.

Authors:  Yongjung Park; Eunhee Lee; Jonghyeon Choi; Seri Jeong; Hyon-Suk Kim
Journal:  J Clin Microbiol       Date:  2012-04-18       Impact factor: 5.948

5.  Human papillomavirus vaccination: current indications and future directions.

Authors:  Leda Gattoc; Navya Nair; Kevin Ault
Journal:  Obstet Gynecol Clin North Am       Date:  2013-05-10       Impact factor: 2.844

6.  Women's intentions to receive cervical cancer screening with primary human papillomavirus testing.

Authors:  Gina S Ogilvie; Laurie W Smith; Dirk J van Niekerk; Fareeza Khurshed; Mel Krajden; Mona Saraiya; Vivek Goel; Barbara K Rimer; Sandra B Greene; Suzanne Hobbs; Andrew J Coldman; Eduardo L Franco
Journal:  Int J Cancer       Date:  2013-07-16       Impact factor: 7.396

Review 7.  Anal cancer and intraepithelial neoplasia screening: A review.

Authors:  Ira L Leeds; Sandy H Fang
Journal:  World J Gastrointest Surg       Date:  2016-01-27

8.  Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.

Authors:  G S Ogilvie; M Krajden; D J van Niekerk; R E Martin; T G Ehlen; K Ceballos; L W Smith; L Kan; D A Cook; S Peacock; G C E Stuart; E L Franco; A J Coldman
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

9.  Monitoring HPV16/18 immunisation in England and elsewhere.

Authors:  S Franceschi
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

10.  Validity and reliability of using a self-lavaging device for cytology and HPV testing for cervical cancer screening: findings from a pilot study.

Authors:  Heidi E Jones; Mahesh M Mansukhani; Guo-Xia Tong; Carolyn L Westhoff
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.